TMCnet News
Research and Markets: Humira (adalimumab) Rheumatoid Arthritis - Forecast and Market Analysis to 2023Research and Markets (http://www.researchandmarkets.com/research/75vb7f/humira) has announced the addition of the "Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering. Humira (adalimumab) is a recombinant, fully-human, IgG1 mAb that binds to TNFa and blocks its interaction with the p55 and p75 cell-surface receptors, which reduces inflammation and prevents tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the market for the treatment of RA. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.
Scope - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Humira (Adalimumab) including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Humira (Adalimumab) for the top 9 countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and China. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 3.4 Quality of Life 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines 4.1.3 Leading Prescribed Drugs for the Treatment of RA 4.1.4 Clinical Practice 5 Competitive Assessment 6 Humira (adalimumab) 6.1 Overview 6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix For more information visit http://www.researchandmarkets.com/research/75vb7f/humira
|
